t******t
发帖数: 15246 | 1 【 以下文字转载自 Biology 讨论区 】
发信人: ttd (oldcat), 信区: Biology
标 题: 信不信由你: we can not rely on most of published data
发信站: BBS 未名空间站 (Tue Sep 6 14:46:08 2011, 美东)
An unspoken rule among early-stage venture capital firms that “at least 50%
of published studies, even those in top-tier academic journals, can't be
repeated with the same conclusions by an industrial lab” has been recently
reported (see Further information) and discussed.
From:
Nature Reviews Drug Discovery
Believe it or not: how much can we rely on published data on potential drug
targets?
Florian Prinz, Thomas Schlange & Khusru Asadullah | t******t
发帖数: 15246 | | z**s
发帖数: 50 | 3 这让我想到，drug研发和制造业不同，虽然做实验也算是体力活，但中国接过clinical
contract research organization产业的看来难度不小，连美国自己实验室的结论重
现性都才有50%，还能指望到中国去做出可靠的结果，即使有了结果是不是还得到美国
的第三方机构再验证一遍？ | g*********o
发帖数: 4653 | 4 这个产业，没办法啊。。
由钱堆出来的烧钱产业，
因为钱的驱动性和peer review的主观性，必然会鱼龙混杂 |
|
